Skip to content

Study on the Effects of Dragon Fruit Tablets on the Human Digestive System and in vitro Fermentation Characteristics

Study on the Effects of Dragon Fruit Tablets on the Human Digestive System and in vitro Fermentation Characteristics

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500109558
Enrollment
Unknown
Registered
2025-09-22
Start date
2025-09-25
Completion date
Unknown
Last updated
2025-09-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

astriction

Interventions

experimental group:Oral dragon fruit tablets, 2 tablets/time, 1 time/day, taken continuously for 14 days.
control group A:Oral starch tablets, 2 tablets/time, 1 time/day, continuously for 14 days.

Sponsors

The Affiliated Hospital of Changchun University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 35 Years

Inclusion criteria

Inclusion criteria: 1. Volunteers aged between 18-35, regardless of gender, with long-term constipation; 2. Healthy volunteers aged between 18-35, regardless of gender, with normal bowel movements; 3. Voluntarily participate in this study, possess autonomous cognitive abilities, and sign an informed consent form; 4. Not using antibiotics or other drugs that may affect gut microbiota in the past 3 months; 5. No serious chronic disease (such as cardiovascular disease, diabetes, digestive system disease, etc.); 6. I have not participated in any other clinical studies within the past month.

Exclusion criteria

Exclusion criteria: 1. Patients who have difficulty taking oral medication due to underlying diseases and other reasons; 2. Accompanied by serious underlying diseases that affect survival, including uncontrolled clinically significant heart, lung, kidney, digestive, hematological diseases, neurological and psychiatric disorders, immune disorders, metabolic disorders, malignant tumors, severe malnutrition, etc; 3. Allergic constitution, those who are allergic to the products involved in the treatment plan; 4. Patients with hypertension, coronary heart disease, diabetes, hyperlipidemia and other diseases are not well controlled by drugs; 5. Impact on gut microbiota, including use of drugs that may affect gut microbiota within the first 3 months of enrollment, daily consumption of probiotics, inflammatory bowel disease, severe intestinal obstruction, inability to obtain feces, etc; 6. According to the researchers' judgment, it is not suitable to use the product population involved in the treatment plan; 7. Physiological period women, pregnant or lactating women; 8. Individuals who are unable to cooperate in their mental state, suffer from mental illnesses, lack self-awareness, and are unable to express themselves clearly.

Design outcomes

Primary

MeasureTime frame
bowel;

Secondary

MeasureTime frame
BMI index;waist circumference;waist-to-hip ratio;body fat percentage;The Four Diagnostic Methods of Traditional Chinese Medicine;

Countries

China

Contacts

Public ContactZhang Jingzhou

The Affiliated Hospital of Changchun University of Chinese Medicine

zjz362@126.com+86 431 8617 7012

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026